Objective: The purpose of this study was to assess survival and morbidity when completion hysterectomy follows radiation for bulky cervical cancer.
Study Design: This was a retrospective observational descriptive review that assessed the survival and morbidity of patients with bulky cervical cancer that was treated with radiation followed by completion hysterectomy between 1993 and 2002. Chemotherapy, external beam radiation, and brachytherapy data were collected.
Results: Fifty-five cases were reviewed. Fifty-three patients received brachytherapy. Twenty-nine patients underwent sensitizing chemotherapy. All patients had hysterectomies. There were 12 early postoperative complications (21.8%) and 10 late complications (19.6%). Eleven patients are dead of disease (21.6%); 3 patients are alive with disease (5.9%), and 37 patients are free of disease (72.5%). Four patients were lost to follow-up. Seven patients who are free of disease had residual cancer in the specimen at hysterectomy.
Conclusion: Complications of combined therapy were comparable to radiation or radical hysterectomy alone. In cases in which an incomplete response to radiation and chemotherapy leaves potential residual carcinoma, adjuvant hysterectomy may be a reasonable treatment option.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ajog.2004.05.076 | DOI Listing |
Cureus
December 2024
Department of Obstetrics and Gynecology, Kastamonu Training and Research Hospital, Kastamonu, TUR.
Mesothelial cysts in the uterus are exceedingly rare. A 41-year-old patient presented with complaints of abdominal pain, and transvaginal ultrasonography revealed an enlarged uterus with a hypoechoic intramural cystic mass measuring 7.2 × 3.
View Article and Find Full Text PDFFront Oncol
December 2024
Department of Obstetrics and Gynecology, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
The distinction between a uterine leiomyosarcoma (uLMS) and a perivascular epithelioid cell neoplasm (PEComa) can be quite challenging. Here we report a 39-year-old woman who underwent a hysteroscopic myomectomy. An intraoperative frozen section pathological examination revealed that the mass was likely to be a mesenchymal malignancy.
View Article and Find Full Text PDFInt J Surg Case Rep
December 2024
Department of Obstetrics and Gynecology, Tishreen University, Lattakia, Syria.
Introduction And Clinical Importance: Placenta previa (PP) is characterized by abnormal placental placement in the lower uterine segment, obstructing the cervical opening. Placenta previa totalis (PPT) occurs when the placenta completely covers the internal cervical os. This condition can lead to placenta accreta spectrum (PAS), where the placenta adheres abnormally to the uterine wall, complicating separation.
View Article and Find Full Text PDFCytojournal
November 2024
Department of Gynecology , Qingdao Women and Children's Hospital, Shandong University, Qingdao, China.
Objective: Deep endometriosis is now referred to as adenomyosis externa, whereas adenomyosis is once known as endometriosis interna. Lysine-specific histone demethylase 1A (KDM1A, commonly LSD1) is a lysine demethylase that targets histone and non-histone proteins. This study aimed to assess how KDM1A affects the migration, invasion, and proliferation of adenomyosis-derived endometrial stromal cells (ESCs).
View Article and Find Full Text PDFUrology
December 2024
Children's Hospital of Philadelphia, Division of Urology.
Uterine RMS is exceedingly rare. The treatment strategy has evolved from aggressive local control with upfront surgery followed by radiation to a more conservative approach with chemotherapy followed by additional treatment pending response, which is outlined in a recent consensus statement from the International Soft-Tissue Sarcoma Consortium. We present a case of a 2-year-old with intermediate risk uterine RMS.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!